## LISTING OF THE CLAIMS

- 1. 3. (Canceled)
- 4. (Previously Presented) An agent for expression of long-term potentiation of synaptic transmission comprising a compound having the following formula [II-1]:

$$R^{4}-Z-N^{E}X-J-Q-R^{7}$$
 [II-1]

wherein

R<sup>4</sup> is acyl,

R<sup>7</sup> is lower alkyl, lower alkoxy, lower alkylamino, lower alkenyl, lower alkenyloxy, lower alkenylamino, lower alkynyl, lower alkynyloxy, lower alkynylamino, cyclo(lower)alkyl, cyclo(lower)alkyloxy, cyclo(lower)alkylamino, aryl, aryloxy, arylamino, a heterocyclic group or amino substituted with a heterocyclic group, each of which may be substituted with suitable substituent(s); or acyl;

Z is a single bond, -CO- or -SO<sub>2</sub>-,

E is lower alkylene optionally substituted with suitable substituent(s),

X is CH or N,

J is a single bond, lower alkylene or

wherein R<sup>8</sup> is hydrogen, lower alkyl, substituted-lower alkyl, an N-protective group, aryl, acyl or a heterocyclic group,

R<sup>5</sup> and R<sup>6</sup> are each hydrogen, lower alkyl, are taken together to form lower alkylene or are taken together to form lower alkylene condensed with a cyclic hydrocarbon or a heterocyclic ring,

provided that when X is N,

then 1) J is a single bond, and Q is -CH<sub>2</sub>-, -CO- or -SO<sub>2</sub>-, or

2) J is lower alkylene,

or pharmaceutically acceptable salts thereof.

5. (Previously Presented) An agent for expression of long-term potentiation of synaptic transmission comprising a compound having the following formula [II-2]:

$$R^4 - N X - J - Q - R^7 \qquad [II-2]$$

wherein

R<sup>4</sup> is acyl,

R<sup>7</sup> is aryl, aryloxy or arylamino, the aryl moiety of all of which may be substituted with halogen; pyridyl; or pyridylamino;

X is CH or N,

J is a single bond, lower alkylene or

wherein  $R^8$  is hydrogen, lower alkyl or an N-protective group,

provided that when X is N, then J is a single bond or lower alkylene,

or pharmaceutically acceptable salts thereof.

- 6. (Previously Presented) The agent for expression of long-term potentiation of synaptic transmission of claim 4, which is an agent for the prophylaxis or treatment of one or more cerebral diseases.
- 7. (Previously Presented) The agent for expression of long-term potentiation of synaptic transmission of claim 6, wherein said cerebral disease is dementia or amnesia.
- 8. (Previously Presented) A method for expressing long-term potentiation of synaptic transmission, comprising administering to a patient in need thereof an effective amount of a compound according to claim 4.
  - 9. 12. (Canceled)
- 13. (Previously Presented) The method for expressing long-term potentiation of synaptic transmission of claim 8, which is a method for the prophylaxis or treatment of one or more cerebral diseases.
- 14. (Previously Presented) The method for expressing long-term potentiation of synaptic transmission of claim 13, wherein said cerebral disease is dementia or amnesia.
  - 15. 21. (Canceled)
- 22. (Previously Presented) A pharmaceutical composition for expression of long-term potentiation of synaptic transmission, which comprises a compound according to claim 4 and a pharmaceutically acceptable carrier or excipient.
  - 23. 26. (Canceled)
- 27. (Previously Presented) The pharmaceutical composition for expression of long-term potentiation of synaptic transmission of claim 22, which is a pharmaceutical composition for the prophylaxis or treatment of one or more cerebral diseases.

- 28. (Previously Presented) The pharmaceutical composition for expression of long-term potentiation of synaptic transmission of claim 27, wherein said cerebral disease is dementia or amnesia.
  - 29. 30. (Canceled)
- 31. (Previously Presented) A method for screening an agent for expression of long-term potentiation of synaptic transmission, which comprises stimulating hippocampal slices, bringing a hippocampal slice into contact with a test compound of claim 4, measuring an amount of somatostatin released from the hippocampal slice and/or a release time thereof, measuring an amount of somatostatin released from a hippocampal slice and/or a release time thereof in the absence of a contact with the test compound, and comparing the amounts and/or the times to calculate the amount of somatostatin released from the hippocampal slice and/or the release time thereof caused by the contact with the test compound.
- 32. (Original) The screening method according to claim 31, which is a screening method of an anti-dementia agent or anti-amnesia agent.
- 33. (Previously Presented) An agent for expression of long-term potentiation of synaptic transmission, wherein the compound having the brain somatostatin activation property is a compound obtained by the screening method of claim 31.
- 34. (Previously Presented) A method for expressing long-term potentiation of synaptic transmission, comprising administering to a patient in need thereof an effective amount of a compound obtained by the screening method of claim 31.
  - 35. (Canceled)
- 36. (Previously Presented) A pharmaceutical composition for expression of long-term potentiation of synaptic transmission which comprises a compound obtained by the screening method of claim 31 and a pharmaceutically acceptable carrier or excipient.

- 37. (Previously Presented) A commercial package comprising the pharmaceutical composition for expression of long-term potentiation of synaptic transmission of claim 22 and a written matter associated therewith, wherein the written matter states that the pharmaceutical composition can or should be used for expression of long-term potentiation of synaptic transmission.
- 38. (Previously Presented) A compound selected by the screening method of claim
  31.
- 39. (Previously Presented) The agent for expression of long-term potentiation of synaptic transmission of claim 5, which is an agent for the prophylaxis or treatment of one or more cerebral diseases.
- 40. (Previously Presented) The agent for expression of long-term potentiation of synaptic transmission of claim 39, wherein said cerebral disease is dementia or amnesia.
- 41. (Previously Presented) A method for expressing long-term potentiation of synaptic transmission, comprising administering to a patient in need thereof an effective amount of a compound according to claim 5.
- 42. (Previously Presented) The method for expressing long-term potentiation of synaptic transmission of claim 41, which is a method for the prophylaxis or treatment of one or more cerebral diseases.
- 43. (Previously Presented) The method for expressing long-term potentiation of synaptic transmission of claim 42, wherein said cerebral disease is dementia or amnesia.
- 44. (Previously Presented) A pharmaceutical composition for expression of long-term potentiation of synaptic transmission, which comprises a compound according to claim 5 and a pharmaceutically acceptable carrier or excipient.

- 45. (Previously Presented) The pharmaceutical composition for expression of long-term potentiation of synaptic transmission of claim 44, which is a pharmaceutical composition for the prophylaxis or treatment of one or more cerebral diseases.
- 46. (Previously Presented) The pharmaceutical composition for expression of long-term potentiation of synaptic transmission of claim 45, wherein said cerebral disease is dementia or amnesia.
- 47. (Previously Presented) A method for screening an agent for expression of long-term potentiation of synaptic transmission, which comprises stimulating hippocampal slices, bringing a hippocampal slice into contact with a test compound of claim 5, measuring an amount of somatostatin released from the hippocampal slice and/or a release time thereof, measuring an amount of somatostatin released from a hippocampal slice and/or a release time thereof in the absence of a contact with the test compound, and comparing the amounts and/or the times to calculate the amount of somatostatin released from the hippocampal slice and/or the release time thereof caused by the contact with the test compound.
- 48. (Previously Presented) The screening method according to claim 47, which is a screening method of an anti-dementia agent or anti-amnesia agent.
- 49. (Previously Presented) An agent for expression of long-term potentiation of synaptic transmission, wherein the compound having the brain somatostatin activation property is a compound obtained by the screening method of claim 47.
- 50. (Previously Presented) A method for expressing long-term potentiation of synaptic transmission, comprising administering to a patient in need thereof an effective amount of a compound obtained by the screening method of claim 47.

Application Serial No. 09/926,641 Response to Office Action mailed July 16, 2003

- 51. (Previously Presented) A pharmaceutical composition for expression of long-term potentiation of synaptic transmission which comprises a compound obtained by the screening method of claim 47 and a pharmaceutically acceptable carrier or excipient.
- 52. (Previously Presented) A commercial package comprising the pharmaceutical composition for expression of long-term potentiation of synaptic transmission of claim 47 and a written matter associated therewith, wherein the written matter states that the pharmaceutical composition can or should be used for expression of long-term potentiation of synaptic transmission.
- 53. (Previously Presented) A compound selected by the screening method of claim 47.
- 54. (Previously Presented) A commercial package comprising the pharmaceutical composition for expression of long-term potentiation of synaptic transmission of claim 31 and a written matter associated therewith, wherein the written matter states that the pharmaceutical composition can or should be used for expression of long-term potentiation of synaptic transmission.